Mga Batayang Estadistika
| LEI | 549300Q914ULWWY95822 |
| CIK | 921299 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to FibroGen, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 2, 2025, the Company announced that it completed the sale of FibroGen International (Hong Kong) Ltd., (including its subsidiaries, “FibroGen China”) to AstraZeneca Treasury Limited (“AstraZeneca”), for a total consideration of approximately $220 million, subject to certain customary adjustments as set forth |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 2, 2025 |
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million Exhibit 99.1 FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million • Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance • Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure • Phase 2 monotherapy trial of FG-324 |
|
| August 18, 2025 |
Exhibit 99.1 FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation • Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, August 18, 2025 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (H |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 14, 2025 |
FOURTH AMENDMENT TO FINANCING AGREEMENT Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 11, 2025 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 11, 2025 |
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update • Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance o Net cash held in China at closing now estimated to be approximately $125 million o Transaction expected to close in 3Q 2025 • Upon close of s |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| July 14, 2025 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 12, 2025 |
FibroGen Announces 1-for-25 Reverse Stock Split Exhibit 99.1 FibroGen Announces 1-for-25 Reverse Stock Split SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen’s common stock will begin trading on a split-adjusted basis |
|
| June 12, 2025 |
Certificate of Amendment of the Amended and Restated Certificate of Incorporation of FibroGen, Inc. Exhibit 3.1 Delaware The First State I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “FIBROGEN, INC.”, FILED IN THIS OFFICE ON THE TENTH DAY OF JUNE, A.D. 2025, AT 1:58 O`CLOCK P.M. AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 04, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 9, 2025 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| June 9, 2025 |
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors Exhibit 99.1 FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors SAN FRANCISCO, June 9, 2025 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. “Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board,” said J |
|
| May 12, 2025 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 12, 2025 |
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update • Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance o Net cash held in China at closing now estimated to be approximately $100 million o Transaction expected to close in 3Q-2025 • Upon close of sa |
|
| May 12, 2025 |
Privileged & Confidential EXECUTION VERSION [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| May 12, 2025 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 12, 2025 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2025 |
Amended and Restated Bylaws of FibroGen, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF FIBROGEN, INC. (A DELAWARE CORPORATION) Bylaws of FibroGen, Inc. Approved by the Board of Directors – April 2, 2025 AMENDED AND RESTATED BYLAWS OF FIBROGEN, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 02, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 31, 2025 |
Exhibit 99.1 FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology • FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer • Initiation of Phase 2 monotherapy dose optimization |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 17, 2025 |
FibroGen Insider Trading and Trading Window Policy, amended and restated as of November 2021. Exhibit 10.6 FIBROGEN, INC. Insider Trading and Trading Window Policy Amended and Restated as of November 2021 Because our stock is publicly traded, you must comply with the provisions of U.S. federal and state securities laws and our policies. During the course of your relationship with FibroGen, Inc. (“FibroGen”), you will learn information about us that is not publicly known. It is illegal for |
|
| March 17, 2025 |
Exhibit 10.5 FIBROGEN, INC. BONUS PLAN The FibroGen, Inc. (“FibroGen” or the “Company”) Bonus Plan (the “Plan”) is a discretionary plan, designed to reward eligible participants for the achievement of corporate goals, as well as individual goals that are consistent with the company’s objectives and organizational priorities on an annual basis. The Plan will govern bonuses paid to eligible particip |
|
| March 17, 2025 |
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results • Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million o Transaction expected to close by mid-2025 • Upon close of sale of FibroGen China, cash runway extended into 2027 • Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-dru |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, IN |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 24, 2025 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280597 Prospectus Supplement (To prospectus dated July 10, 2024) $30,000,000 Common Stock We have entered into an ATM Equity Offering Sales Agreement, or Sales Agreement, with BofA Securities, Inc., or BofA, as our sales agent, dated February 24, 2025, relating to the sale from time to time of shares of our common stock, |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 24, 2025 |
Exhibit 1.1 FIBROGEN, INC. Common Stock ($0.01 par value) Having an Aggregate Offering Price of up to $30 Million ATM EQUITY OFFERINGSM SALES AGREEMENT February 24, 2025 BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: FibroGen, Inc., a Delaware corporation (the “Company”) confirms its agreement (this “Agreement”) with BofA Securities, Inc. (the “Manager”) as fo |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 20, 2025 |
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million Exhibit 99.1 FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million • Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million • Upon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 16, 2024 |
FibroGen Appoints David DeLucia as Chief Financial Officer Exhibit 99.1 FibroGen Appoints David DeLucia as Chief Financial Officer SAN FRANCISCO, December 16, 2024 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wet |
|
| November 14, 2024 |
FGEN / FibroGen, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-fgen093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* FIBROGEN, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 31572Q808 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 12, 2024 |
FibroGen Reports Third Quarter 2024 Financial Results Exhibit 99.1 FibroGen Reports Third Quarter 2024 Financial Results • Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025 • Initiation of Phase 2 monotherapy dose optimization |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBRO |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 12, 2024 |
FGEN / FibroGen, Inc. / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 fgena6111124.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* FibroGen, Inc. (Name of Issuer) COM (Title of Class of Securities) 31572Q808 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| October 3, 2024 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2024 |
EX-FILING FEES 4 fgen-exfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) FibroGen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amou |
|
| August 7, 2024 |
As filed with the Securities and Exchange Commission on August 7, 2024 S-8 1 forms-82024.htm S-8 As filed with the Securities and Exchange Commission on August 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or other jurisdiction of incorporation or organ |
|
| August 6, 2024 |
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update • Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75% • Focus R&D investment on FG-3246 and PET46, a first-in-class anti-CD46 antibody-drug conjugate and companio |
|
| August 6, 2024 |
Form of Restricted Stock Unit Grant Notice and Award Agreement Exhibit 10.4 Fibrogen, Inc. Restricted Stock Unit Grant Notice (2024 Equity Incentive Plan) Fibrogen, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and co |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 6, 2024 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 6, 2024 |
CONFIDENTIAL EXECUTION VERSION [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 6, 2024 |
Form of Stock Option Grant Notice and Option Agreement Exhibit 10.5 FibroGen, Inc. Stock Option Grant Notice (2024 Equity Incentive Plan) FibroGen, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreeme |
|
| July 9, 2024 |
VIA EDGAR July 9, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 28, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) FibroGen, Inc. |
|
| June 28, 2024 |
As filed with the U.S. Securities and Exchange Commission on June 28, 2024 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 28, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or other jurisdiction of incorporation or or |
|
| June 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 26, 2024 |
Virtual KOL Investor Event Series Part II: Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer Hosted by FibroGen Inc. |
|
| June 7, 2024 |
FibroGen, Inc. 2024 Equity Incentive Plan. Exhibit 10.1 FibroGen, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: April 22, 2024 Approved by the Stockholders: June 5, 2024 1. General. (a) Successor to and Continuation of Prior Plan. (i) The Plan is the successor to and continuation of the FibroGen, Inc. 2014 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Pacific time on the Effective Date, no additio |
|
| June 7, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 6, 2024 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 6, 2024 |
Non-Employee Director Compensation Policy, as amended, dated April 22, 2024. Exhibit 10.3 FibroGen, Inc. Non-Employee Director Compensation Policy This Non-Employee Director Compensation Policy (the “Policy”) documents the terms and conditions of the cash and equity compensation that non-employee members of the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) may earn for their service on the Board from and after the initial public offering of the common sto |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| May 6, 2024 |
Offer Letter by and between FibroGen, Inc. and Deyaa Adib, M.D., dated February 6, 2024. Exhibit 10.4 February 6, 2024 Deyaa R. Adib, MD [*] Dear Deyaa, FibroGen, Inc. is pleased to offer you the position of SVP, Chief Medical Officer reporting to Thane Wettig, Chief Executive Officer. The effective date ("Effective Date") of your employment will be set, as mutually agreed upon in advance with FibroGen, Inc. (“FibroGen”) and confirmed with Human Resources. Your primary work location w |
|
| May 6, 2024 |
Exhibit 99.1 FibroGen Reports First Quarter 2024 Financial Results • Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024 • Topline data from LAPIS Phase 3 study in locally advanced unresectable pancreatic cancer anticipated in 3Q 2024 • Reported compelling data from Phase 1 monotherapy study of |
|
| May 6, 2024 |
Execution Copy [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, IN |
|
| February 26, 2024 |
Exhibit 99.1 FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results • Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in 1Q 2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 26, 2024 |
FIBROGEN, INC. BONUS PLAN Exhibit 10.5 The FibroGen, Inc. (“FibroGen” or the “Company”) Bonus Plan (the “Plan”) is a discretionary plan, designed to reward eligible participants for the achievement of corporate goals, as well as individual goals that are consistent with the company’s objectives and organizational priorities on an annual basis. The Plan will govern bonuses paid to eligible particip |
|
| February 26, 2024 |
Policy for Recoupment of Incentive Compensation Exhibit 97.1 FibroGen, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee of the Board of Directors (the “Compensation Committee”, and the “Board”) of FibroGen, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) |
|
| February 26, 2024 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| February 14, 2024 |
FGEN / FibroGen, Inc. / Point72 Asset Management, L.P. - FIBROGEN, INC. Passive Investment SC 13G/A 1 p24-0805sc13ga.htm FIBROGEN, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Fibrogen, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 31572Q808 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2024 |
FGEN / FibroGen, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-fgen123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* FIBROGEN, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 31572Q808 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 13, 2024 |
FGEN / FibroGen, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0921-fibrogeninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: FibroGen Inc Title of Class of Securities: Common Stock CUSIP Number: 31572Q808 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p |
|
| February 12, 2024 |
FGEN / FibroGen, Inc. / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 fgena521224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* FibroGen, Inc. (Name of Issuer) COM (Title of Class of Securities) 31572Q808 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBRO |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 6, 2023 |
Exhibit 99.1 FibroGen Reports Third Quarter 2023 Financial Results • Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer • Third quarter net revenue of $40.1 million, an increase of 155% year over year • Roxadustat sNDA accepted |
|
| October 27, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 02, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 6, 2023 |
Consulting Agreement, dated September 11, 2023, between FibroGen, Inc. and Mark Eisner. Exhibit 10.1 Consulting Agreement This Consulting Agreement (“Agreement”) is effective as of September 11, 2023 (“Effective Date”), by and between FibroGen, Inc., a Delaware corporation with its principal offices located at 409 Illinois Street, San Francisco, California 94158 and its subsidiaries (collectively “FibroGen”) and Mark Eisner, an individual residing at [PRIVATE ADDRESS] (“Consultant”). |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 29, 2023 |
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy – Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, August 29, 2023 (GLOBE NEWSWIRE) - FibroGen, Inc. |
|
| August 29, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2023 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 7, 2023 |
Evaluation Agreement by and between FibroGen, Inc. and Fortis Therapeutics, Inc., dated May 5, 2023. CONFIDENTIAL EXECUTION VERSION [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2023 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 7, 2023 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 7, 2023 |
Exhibit 99.1 FibroGen Reports Second Quarter 2023 Financial Results • Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer • Robust roxadustat volume growth of over 40% in China • Entered into exclusive license for FOR46, a first-in-class CD46-targe |
|
| August 7, 2023 |
Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| August 7, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) FibroGen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2014 Equity Incentive Pl |
|
| August 7, 2023 |
As filed with the Securities and Exchange Commission on August 7, 2023 As filed with the Securities and Exchange Commission on August 7, 2023 Registration No. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 25, 2023 |
Consulting Agreement, dated July 23, 2023, between FibroGen, Inc. and Enrique Conterno. Exhibit 10.2 Consulting Agreement This Consulting Agreement (“Agreement”) dated as of July 23, 2023, is effective as of August 9, 2023 (“Effective Date”), by and between FibroGen, Inc., a Delaware corporation with its principal offices located at 409 Illinois Street, San Francisco, California 94158 and its subsidiaries (collectively “FibroGen”) and Enrique Conterno, an individual residing at 3014 |
|
| July 25, 2023 |
Exhibit 99.1 FibroGen Announces Leadership Transition Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN), today announced the appointment of Thane Wettig as the Company’s interim Chief Executive Officer effective as of Jul |
|
| July 25, 2023 |
Offer Letter, dated July 23, 2023, between FibroGen, Inc. and Thane Wettig. Exhibit 10.1 July 23, 2023 Thane Wettig 915 Oak Terrace Road Westfield, IN 46074 Dear Thane, FibroGen, Inc. (“FibroGen” or the “Company”) is pleased to offer you the position of Interim Chief Executive Officer (“Interim CEO”), reporting to the Board of Directors (the “Board”), effective July 23, 2023 (the "Effective Date"). The terms of your employment will remain as currently in effect, with the |
|
| July 19, 2023 |
FGEN / FibroGen Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 FIBROGEN, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 31572Q808 (CUSIP Number) JULY 13, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 26, 2023 |
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis Study did not meet the primary endpoint Pamrevlumab was generally safe and well tolerated ZEPHYRUS-2 Phase 3 study will be discontinued Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 - FibroGen, Inc. |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 7, 2023 |
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy – Study did not meet the primary endpoint – Pamrevlumab was generally safe and well tolerated – Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 SAN FRANCISCO, June 7, 2023 (GLOBE NEWSWIRE) - FibroGen, Inc. |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 18, 2023 |
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia • Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa • Plan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) - FibroGen, Inc. |
|
| May 8, 2023 |
FibroGen, Inc. Non-Employee Director Compensation Policy, as amended. Exhibit 10.3 FibroGen, Inc. Non-Employee Director Compensation Policy This Non-Employee Director Compensation Policy (the “Policy”) documents the terms and conditions of the cash and equity compensation that non-employee members of the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) may earn for their service on the Board from and after the initial public offering of the common sto |
|
| May 8, 2023 |
EXECUTION VERSION [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 8, 2023 |
Form of Executive Officer Change in Control and Severance Agreement. Form of Agreement Exhibit 10.4 FIBROGEN, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (this “Agreement”) is dated as of , 20 (the “Effective Date”), by and between [] (“Executive”) and FibroGen, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Executive with certain benefits described herein upon the occurrence of |
|
| May 8, 2023 |
Exhibit 99.1 FibroGen Reports First Quarter 2023 Financial Results • Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into Exclusive License for FOR46 with Fortis Therapeutics SAN FRANCISCO, May 8, 2023 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today reported financ |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| February 27, 2023 |
EXECUTION VERSION [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| February 27, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| February 27, 2023 |
FibroGen, Inc. Non-Employee Director Compensation Policy, as amended. Exhibit 10.4 FibroGen, Inc. Non-Employee Director Compensation Policy This Non-Employee Director Compensation Policy (the “Policy”) documents the terms and conditions of the cash and equity compensation that non-employee members of the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) may earn for their service on the Board from and after the initial public offering of the common sto |
|
| February 27, 2023 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-266663 Prospectus Supplement dated February 27, 2023 (To prospectus dated August 8, 2022) $200,000,000 Common Stock This prospectus supplement, or Supplement, supplements the prospectus, dated August 8, 2022, or Prospectus, relating to the offer and sale of shares of common stock, par value $0.01 per share, of FibroGen, Inc. from time to |
|
| February 27, 2023 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| February 27, 2023 |
Exhibit 99.1 FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, February 27, 2023 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2022 and p |
|
| February 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, IN |
|
| February 27, 2023 |
Exhibit 10.44 fibrogen, inc. Common Stock ($0.01 par value) Having an Aggregate Offering Price of up to $200 Million Amended and Restated Equity Distribution Agreement February 27, 2023 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: Reference is made to the Equity Distribution Agreement, dated August 8 |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Fibrogen, Inc. (Title of Class o |
|
| February 9, 2023 |
FGEN / FibroGen Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: FibroGen Inc. Title of Class of Securities: Common Stock CUSIP Number: 31572Q808 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 9, 2023 |
FGEN / FibroGen Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 fgena420923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* FibroGen, Inc. (Name of Issuer) COM (Title of Class of Securities) 31572Q808 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 7, 2022 |
FibroGen Reports Third Quarter 2022 Financial Results Exhibit 99.1 FibroGen Reports Third Quarter 2022 Financial Results • Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 • Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023 • Strong roxadustat volume growth in Ch |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBRO |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| August 8, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) FIBROGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 8, 2022 |
FibroGen Reports Second Quarter 2022 Financial Results Exhibit 99.1 FibroGen Reports Second Quarter 2022 Financial Results ? Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy ? 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021 ? Continued significant roxadustat volume growth in China SAN FRANCISCO, August 8, 2022 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today repor |
|
| August 8, 2022 |
Exhibit 1.2 FIBROGEN, INC. Common Stock ($0.01 par value) Having an Aggregate Offering Price of up to $200 Million Equity Distribution Agreement August 8, 2022 Goldman, Sachs & Co. LLC 200 West Street New York, New York 10282 Ladies and Gentlemen: FibroGen, Inc., a Delaware corporation (the ?Company?) confirms its agreement (this ?Agreement?) with Goldman, Sachs & Co. LLC (the ?Manager?) as follow |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| August 8, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) FibroGen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2014 Equity Incentive Pl |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2022 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 FIBROGEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36740 77-0357827 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| May 9, 2022 |
Exhibit 10.1 Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT by and among FIBROGEN, INC. and its AFFILIATES and ELUMINEX BIOSCIENCES (SUZHOU) LIMITED AMENDED |
|
| May 9, 2022 |
Exhibit 99.1 FibroGen Reports First Quarter 2022 Financial Results ? Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis ? 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 ? Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction SAN FRANCISCO, May 9, 2022 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) t |
|
| April 29, 2022 |
DEF 14A 1 fgen-def14a20220616.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 9, 2022 |
FGEN / FibroGen Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: FibroGen Inc. Title of Class of Securities: Common Stock CUSIP Number: 31572Q808 Date of Event Which Requires Filing of this Statement: February 28, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 00 |
|
| February 28, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| February 28, 2022 |
Exhibit 99.1 FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results ? Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer ? Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy ? Total company revenue increased from $176.3 million in 2020 to $235.3 million in 2021 SAN FRANCISCO, Februa |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, IN |
|
| February 11, 2022 |
VIA EDGAR February 11, 2022 U.S. Securities and Exchange Staff Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Christine Westbrook RE: FibroGen, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 001-36740 Ladies and Gentlemen: FibroGen, Inc. (?FibroGen? or the ?Company? or ?we?) is submitting th |
|
| February 10, 2022 |
FGEN / FibroGen Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 f021022a.htm SCHEDULE 13G 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Fibrogen, Inc. (Title of Class of Securities) Common |
|
| February 10, 2022 |
FGEN / FibroGen Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: FibroGen Inc. Title of Class of Securities: Common Stock CUSIP Number: 31572Q808 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 10, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 10, 2022 |
FGEN / FibroGen Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* FibroGen, Inc. (Name of Issuer) COM (Title of Class of Securities) 31572Q808 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| January 20, 2022 |
VIA EDGAR January 20, 2022 U.S. Securities and Exchange Staff Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Christine Westbrook RE: FibroGen, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 001-36740 Ladies and Gentlemen: FibroGen, Inc. (?FibroGen? or the ?Company? or ?we?) is submitting thi |
|
| December 16, 2021 |
CORRESP 1 filename1.htm VIA EDGAR December 15, 2021 U.S. Securities and Exchange Staff Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Sasha Parikh Kevin Vaughn Suzanne Hayes RE: FibroGen, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 001-36740 Ladies and Gentlemen: FibroGen, Inc. (“FibroGen” or the “ |
|
| November 9, 2021 |
Exhibit 99.1 FibroGen Reports Third Quarter 2021 Financial Results ? Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas ? Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis ? Total roxadustat net sales in China of $57.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZenec |
|
| November 9, 2021 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| November 9, 2021 |
Offer Letter by and between FibroGen, Inc. and Juan Graham, effective as of July 30, 2021. Exhibit 10.2 July 27, 2021 Prepared For: Juan Graham Dear Juan, FibroGen, Inc. is pleased to offer you the position of Chief Financial Officer reporting to me. The commencement date of your employment (the "Effective Date") will be set, as mutually agreed upon in advance with FibroGen, Inc. (?FibroGen?) and confirmed with Human Resources according to the terms of this offer. This offer of employme |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBRO |
|
| November 9, 2021 |
Transition Agreement by and between FibroGen, Inc. and Pat Cotroneo, dated as of August 14, 2021. Exhibit 10.3 August 14, 2021 Pat Cotroneo Via E-mail Re: Transition Agreement Dear Pat: This letter sets forth the terms of the transition agreement (the ?Agreement?) which you and FibroGen, Inc. (the ?Company?) have agreed in the context of your employment transition. 1.Separation Date. Subject to the terms and conditions of this Agreement, your employment with the Company will continue through M |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 20, 2021 |
Exhibit 99.1 Astellas Receives European Commission Approval for First-in-Class EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe TOKYO, August 19, 2021 ? Astel |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 16, 2021 |
Exhibit 99.1 FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September 6, 2021, and will remain w |
|
| August 11, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 11, 2021 |
Exhibit 99.1 FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease SAN FRANCISCO, AUGUST 11, 2021 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic k |
|
| August 9, 2021 |
Exhibit 99.1 FibroGen Reports Second Quarter 2021 Financial Results ? Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. ? Total roxadustat net sales in China of $52.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca ? Roxadustat Receives Positive Opinion from the CHMP of EMA for Patients with Anemia of CKD ? Roxadustat Receives |
|
| August 9, 2021 |
Exhibit 10.1 SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this ?Sixth Amendment?) is made as of June 1, 2021 (the ?Effective Date?), by and between ARE- SAN FRANCISCO NO. 43, LLC, a Delaware limited liability company (?Landlord?), and FIBROGEN, INC., a Delaware corporation (?Tenant?). RECITALS A.Landlord (as successor-in-interest to X-4 Dolphin LLC) and Tenant are parties to that certai |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 9, 2021 |
As filed with the Securities and Exchange Commission on August 9, 2021 As filed with the Securities and Exchange Commission on August 9, 2021 Registration No. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| August 9, 2021 |
Subsidiaries of FibroGen, Inc. Exhibit 21.1 List of Subsidiaries of FibroGen, Inc. Subsidiaries Incorporation Beijing Falikang Pharmaceutical Co., Ltd. China FibroGen (China) Medical Technology Development Co., Ltd. China FibroGen China Anemia Holdings, Ltd. Cayman Islands FibroGen Europe Oy Finland FibroGen International (Cayman) Limited Cayman Islands FibroGen International (Hong Kong) Limited Hong Kong FibroGen INTL LLC Dela |
|
| August 9, 2021 |
Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| July 20, 2021 |
EX-99.1 2 fgen-ex9916.htm EX-99.1 Exhibit 99.1 Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform • Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea • Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea • Biosynthetic Cornea Designed t |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 25, 2021 |
Exhibit 99.1 Press Release Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease TOKYO, June 25, 2021 ? Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for Medicinal Products for H |
|
| June 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 17, 2021 |
Exhibit 99.1 FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease ? FibroGen Exclusively Licenses HiFiBiO?s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs ? Transformative Transaction for FibroGen?s Early-stage Pipeline ? HiFiBiO to Receive $25 Million Upfront, and Up to a |
|
| June 7, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 27, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 10, 2021 |
EX-10.1 2 fgen-ex101120.htm EX-10.1 Exhibit 10.1 November 27, 2020 K. Peony Yu Via E-mail Re: Transition, Separation, and Consulting Agreement Dear Peony: This letter sets forth the terms of the transition, separation, and consulting agreement (the “Agreement”) which you and FibroGen, Inc. (the “Company”) have agreed in the context of your employment transition. 1.Separation Date. Subject to the t |
|
| May 10, 2021 |
Exhibit 99.1 FibroGen Reports First Quarter 2021 Financial Results ?Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis ?Total roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca, compared to $29.2 million last quarter ?FDA to hold Advisory Committee Meeting on Roxadustat NDA - tentative date Jul |
|
| May 10, 2021 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 10, 2021 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 13, 2021 |
definitive proxy statement on Schedule 14A DEF 14A 1 fgen-def14a20210526.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 7, 2021 |
EX-99.1 2 fgen-ex9916.htm EX-99.1 Exhibit 99.1 FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021 SAN FRANCISCO, APRIL 6, 2021 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal |
|
| April 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 6, 2021 |
EX-99.1 2 fgen-ex9916.htm EX-99.1 Exhibit 99.1 FibroGen Provides Additional Information on Roxadustat Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) SAN FRANCISCO – April 6, 2021 – FibroGen, Inc. (Nasdaq: FGEN) (the “Company”) today provided clarification of certain prior disclosur |
|
| March 1, 2021 |
Subsidiaries of FibroGen, Inc. EX-21.1 5 fgen-ex211241.htm EX-21.1 Exhibit 21.1 List of Subsidiaries of FibroGen, Inc. Subsidiaries Incorporation Beijing Falikang Pharmaceutical Co., Ltd. China FibroGen (China) Medical Technology Development Co., Ltd. China FibroGen China Anemia Holdings, Ltd. Cayman Islands FibroGen Europe Oy Finland FibroGen International (Cayman) Limited Cayman Islands FibroGen International (Hong Kong) Limi |
|
| March 1, 2021 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| March 1, 2021 |
Offer Letter, by and between FibroGen, Inc. and Mark Eisner, dated as of October 22, 2020. EX-10.44 4 fgen-ex1044204.htm EX-10.44 Exhibit 10.44 October 22, 2020 Mark Eisner, M.D., M.P.H. [PRIVATE ADDRESS] Dear Mark, FibroGen, Inc. is pleased to offer you the position of Chief Medical Officer reporting to me. The effective date of your employment ("Effective Date") will be set, as mutually agreed upon in advance with FibroGen, Inc. (“FibroGen”) and confirmed with Human Resources. This of |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, IN |
|
| March 1, 2021 |
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results • Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million • FDA to hold Advisory Committee Meeting on Roxadustat New Drug Application SAN FRANCISCO, March 1, 2021 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth qu |
|
| March 1, 2021 |
EX-10.36 3 fgen-ex1036605.htm EX-10.36 EXECUTION COPY [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. Exhibit 10.36 SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT – CLINICAL PRODUCT DRUG SUBSTANCE WHEREAS, this Clinic |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: FibroGen Inc. Title of Class of Securities: Common Stock CUSIP Number: 31572Q808 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 27, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 7, 2021 |
SC 13G/A 1 tm211778d3sc13ga.htm SC 13G/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . .10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* FibroGen, Inc. (Name of Issuer) Common (Title of Class of Securities) 31572Q808 (CUSIP |
|
| December 18, 2020 |
FibroGen Provides Regulatory Update on Roxadustat Exhibit 99.1 FibroGen Provides Regulatory Update on Roxadustat SAN FRANCISCO, December 18, 2020 (GLOBE NEWSWIRE) – FibroGen, Inc. (Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) by three months. The updated Prescription Drug Use |
|
| December 18, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2020 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 5, 2020 |
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| November 5, 2020 |
Exhibit 99.1 FibroGen Reports THIRD Quarter 2020 Financial Results - Strong third Quarter China Roxadustat Net Sales of $22.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN FRANCISCO, November 5, 2020 – FibroGen, Inc. (NASDAQ:FGEN) reported financial results for the third quarter of 2020 and provided an update on the company’s recent developments. “I am pl |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 5, 2020 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| November 5, 2020 |
EX-10.2 3 fgen-ex10299.htm EX-10.2 EXECUTION VERSION CONFIDENTIAL [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. Exhibit 10.2 AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certai |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBRO |
|
| November 5, 2020 |
Exhibit 10.3 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (CHINA) between FIBROGEN CHINA ANEMIA HOLDINGS, LTD.; BEIJING FIBROGEN MEDICAL TECHNOLOGY |
|
| November 5, 2020 |
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| November 5, 2020 |
EX-10.7 8 fgen-ex107101.htm EX-10.7 Exhibit 10.7 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. LICENSE AGREEMENT This License Agreement (the “Agreement”), effective, subject to Article 22, upon the Effective Time (as defi |
|
| November 5, 2020 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| November 5, 2020 |
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| November 5, 2020 |
Exhibit 10.8 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. Amendment No. 2 To Master Supply Agreement This Amendment No. 2 (the “Second Amendment”) is effective as of July 24, 2020 (the “Second Amendment Effective Date”) by |
|
| August 6, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 FibroGen, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36740 77-0357827 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 6, 2020 |
Exhibit 99.1 FibroGen Announces New Appointments to its Board of Directors - Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) - - Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at the Scripps Research Institute - SAN FRANCISCO, August 6, 2020 (GLOBE NEWSWIRE) - FibroGen, Inc. (NASDAQ:FGEN |
|
| August 6, 2020 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed. |
|
| August 6, 2020 |
Offer Letter, by and between FibroGen, Inc. and Thane Wettig, dated as of May 7, 2020. Exhibit 10.1 May 7, 2020 Thane Wettig [PRIVATE ADDRESS] Dear Thane, FibroGen, Inc. is pleased to offer you the position of Chief Commercial Officer reporting to Enrique Conterno, Chief Executive Officer. The effective date ("Effective Date") of your employment will be set, as mutually agreed upon in advance with FibroGen, Inc. (“FibroGen”) and confirmed with Human Resources. This offer of employme |
